AFAP1 and non-small cell lung carcinoma: The mean overall survival time for NSCLC patients with high levels of AFAP1‐AS1 ORF2 peptide was only 46.0 months, whereas survival for NSCLC patients with low levels of AFAP1‐AS1 ORF2 peptide was 72.0 months.